China 
Africa 
Explore chapters and articles related to this topic
Dalbavancin
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Marguerite L. Monogue, David P. Nicolau
The initial FDA-approved dosage consisted of dalbavancin, 1000 mg on the first day, followed by 500 mg 7 days later, which was well tolerated and associated with a higher clinical response rate than the comparator regimens (Dorr et al., 2005; Durata, 2015). This regimen is also approved in Europe by the European Medicines Agency. Recently, the FDA approved a single 1500-mg infusion of dalbavancin based on a phase III study, which demonstrated that the single dose was noninferior to the two-dose regimen and has a similar safety profile. This single-dose regimen potentially removes logistical constraints related to delivery of the second dose, enhancing its ease of use (Dunne et al., 2016a; Dunne et al., 2016b).
Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol
Published in Journal of Chemotherapy, 2023
Emanuele Durante-Mangoni, Alessandro Riccardi, Mario Guarino, Flavio Cesaro, Marina Lugarà, Silvia Mascolo, Lucia Morelli, Vincenzo Natale, Massimo Andreoni
A photo of the lesion (to be delimited with a pencil) will be obtained by means of a smartphone and shared among patient/caregiver and physician investigators. Then, a single dose of dalbavancin (1500 mg or lower, according to renal function) will be administered by intravenous infusion. Prior to discharge, patients will be instructed on how to access the telehealth system (based on a dedicated smartphone App which will be developed by investigators) and what information will be required. Specifically, they will be requested to upload a follow up clinical image to the electronic health record every day for the first 4 days and then at 7, 14, 21 and 28 days post discharge. To this aim, upon discharge from the ED, the lesion will be circumscribed with a skin marking pen. The patient and/or the caregiver will receive specific explanation as to how to take follow up photos, including: (i) need to extend the photograph framing 2 cm beyond the skin mark; (ii) use of the same lighting, possibly natural light; (iii) maintaining the limb/body part in the horizontal position with the patient lying supine in bed; (iv) checking the image focus.
Accuracy of gradient diffusion method for susceptibility testing of dalbavancin and comparators
Published in Expert Review of Anti-infective Therapy, 2022
A. G. Leroy, V. Lavigne-Quilichini, P. Le Turnier, B. Loufti, E. Le Breton, C. Piau, M. Kempf, A. Pantel, M. Amara, C. Neuwirth, R. Sanchez, J. Guinard, J. F. Huon, M. Grégoire, S. Corvec
Initially approved in acute bacterial skin and soft tissue infections, dalbavancin has predominantly been used in off-labeled indications (e.g. bone and joint infections and endocarditis) [5]. Indeed, dalbavancin with its PK-PD properties is an interesting anti-Gram-positive agent but its cost limits its use. PK-PD optimization based on MICs and therapeutic drug monitoring could be useful then [6]. This work raises the question of whether the routinely daily practice GD testing can constitute a reliable and appropriate method to determine dalbavancin susceptibility. Indeed, (i) EUCAST 2020 guidelines only recommend BMD methods for dalbavancin AST, (ii) few commercial BMD methods are currently available to determine dalbavancin MICs, (iii) available data regarding the use of GD methods for dalbavancin MICs testing remain scarce.
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives
Published in Expert Review of Anti-infective Therapy, 2021
Massimo Andreoni, Matteo Bassetti, Salvatore Corrao, Francesco Giuseppe De Rosa, Vincenzo Esposito, Marco Falcone, Paolo Grossi, Federico Pea, Nicola Petrosillo, Carlo Tascini, Mario Venditti, Pierluigi Viale
In order to review the literature on the potential uses of dalbavancin, including on and off-label indications, like non-ABSSSI infections, and to assess the most suitable administration regimens, a group of experts was organized. Specialists belonging to different medical areas convened, namely infectious diseases (ID) specialists and a clinical pharmacologist. A total of two consensus conferences took place during which the available evidence on dalbavancin were evaluated. Specifically, a search in the literature using validated keywords filters to select articles regarding dalbavancin was performed: dalbavancin, Gram-positive infections, Gram-positive cocci, ABSSSI, intravenous treatment, and long-acting antibiotics. A literature research on biomedical bibliographic databases (PubMed and Embase) was carried out from the year 2004 up to 30 September 2020, and research papers, reviews, and meta-analyses were considered. The manuscript draft was revised by all authors, who approved the final version before submission.